drugset
drugset / Trial / NCT01998672

Multiple Ascending Oral Dose Phase I Study With Px-102

NCT01998672 ↗

Phase 1 Completed 42 enrolled Phenex Pharmaceuticals AG
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of the FXR agonist Px-102 in healthy subjects after 7 days multiple oral dosing.

Timeline

Start
2012-02
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Px-102 Small molecule 0.5 mg/kg Oral
Comparator Px-102 Small molecule 1 mg/kg Oral
Comparator Px-102 Small molecule 1.5 mg/kg Oral

Indications

No indication recorded.